Wall Street's Bull Case for Bristol Myers Squibb Is Getting Louder

Key Points Bristol Myers Squibb's stock is up more than 17% so far this year. The company could be acquired by AstraZeneca. Bristol Myers Squibb has increased its dividend for 17 consecutive years. 10 stocks we like better than Bristol Myers Squibb › Bristol Myers Squibb (NYSE: BMY) is up a little more than 17% so far this year. Analysts don't seem that optimistic about the pharmaceutical stock , with an average price target of $66.71, just over $3 above its current trading price. The bear case for the stock is that several of its top sellers, including Eliquis and Opdivo, are facing patent expirations. However, that's discounting the rise in the company's growth portfolio. Here are three reasons why the bull case for the stock is getting louder.